Latest News and Press Releases

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indicationUpdate on BALLAD study GO/NO GO decisionConference call scheduled for today, December 20,...

Study did not meet primary or secondary endpointsFavorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am...

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to...

November 1, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized...

$329 million in third quarter global net product salesOn track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host...

October 24, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...

VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated...

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV)...

August 30, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...